Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1998-11-16
2000-08-15
Fay, Zohreh
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514331, A61K 31725, A61K 31445
Patent
active
061037052
ABSTRACT:
The invention is also directed to pharmaceutical composition comprising a compound having anti-Xa activity, a platelet aggregation antagonist compound and a pharmaceutically acceptable carrier. The invention is also directed to a method of treating or preventing a thrombogenic condition associated with a thrombosis related ischemic disorder in a patient comprising administering to said patient pharmaceutically effective amounts of a compound having anti-Xa activity and a platelet aggregation antagonist compound. In addition, this invention is directed to the use of pharmaceutically effective amounts of a compound having anti-Xa activity and a platelet aggregation antagonist compound in the preparation of a medicament for treating or preventing a physiological condition associated with thrombosis related ischemic disorder. Furthermore, this invention is directed to a kit for treating or preventing a physiological condition associated with thrombosis related ischemic disorder, said kit comprising a plurality of separate containers, wherein at least one of said containers contains a compound having anti-Xa activity and at least another of said containers contains a platelet aggregation antagonist compound, and said containers optionally contain a pharmaceutical carrier.
REFERENCES:
patent: 3766167 (1973-10-01), Lasker et al.
patent: 4438108 (1984-03-01), Sanders et al.
patent: 4486420 (1984-12-01), Lormeau et al.
patent: 4533549 (1985-08-01), Lasker
patent: 4629699 (1986-12-01), Bianchini
patent: 4683291 (1987-07-01), Zimmerman et al.
patent: 4692435 (1987-09-01), Lormeau et al.
patent: 4804652 (1989-02-01), Lormeau et al.
patent: 4826827 (1989-05-01), Lormeau et al.
patent: 4857508 (1989-08-01), Adams et al.
patent: 4879313 (1989-11-01), Tjoeng et al.
patent: 4952562 (1990-08-01), Klein et al.
patent: 4992463 (1991-02-01), Tjoeng et al.
patent: 5023233 (1991-06-01), Nutt et al.
patent: 5037808 (1991-08-01), Tjoeng et al.
patent: 5051405 (1991-09-01), Klein et al.
patent: 5053392 (1991-10-01), Klein et al.
patent: 5064814 (1991-11-01), Klein et al.
patent: 5086069 (1992-02-01), Klein et al.
patent: 5100875 (1992-03-01), Marguerie de Rotrou
patent: 5292756 (1994-03-01), Duggan et al.
patent: 5639469 (1997-06-01), Benes et al.
patent: 5721214 (1998-02-01), Marlowe et al.
patent: 5763427 (1998-06-01), Wertz et al.
Wenzl et al., Loss of Extremities in Heparin-Induced Thrombocytopenia, Unfallchirurg 99:607-611 (1996).
Genetta et al., Abciximab: A New Antiaggregant Used in Angioplasty, The Annals of Pharmacotherapy, (30) 251-257 (1996).
Riessen et al., Prospects for Site-Specific Delivery of Pharmacologic and Molecular Therapies, JACC 23(5), 1234-1244 (1994).
Topol et al., Randomised trial of coronary intervention with antibody against platelet 11b/111a integrin for reduction of clinical restenosis: results at six months, The Lancet 343, 881-886 (1994).
Cremonesi et al., Structural And Biological Aspects of Low-Molecular Weight Heparins, Drugs of the Future 12(1), 45-64 (1987).
Plow et al., Inhibition of fibrinogen binding to human platelets by the tetrapeptide glycyl-L-arginyl-L-proline, Proc. Natl. Acad. Sci., USA 79, 3711-3715 (1982).
Ruggeri et al., Inhibition of platelet function with synthetic peptides designed to be high-affinity antagonists of fibrinogen binding to platelets, Proc. Natl. Acad. Sci., USA 83, 5708-5712 (1986).
Plow et al., The effect of Arg-Gly-Asp-containing peptides on fibrinogen and von Willebrand factor binding to platelets, Proc. Natl. Acad. Sci. USA 82, 8057-8061 (1985).
Cook et al., The Effects of Two Synthetic Glycoprotein 11b/111a Antagonists, Ro 43-8857 and L-700,462, on Platelet Aggregation and Bleeding in Guinea-Pigs and Dogs: Evidence that Ro 43-8857 Is Orally Active, Thrombosis & Haemostasis 70(5), 883-847 (1993).
Kereiakes et al., Randomized, Double-Bline, Placebo-Controlled Dose-Ranging Study of Tirofiban (MK-383) Platelet 11b/111a Blockade in High Risk Patients Undergoing Coronary Angioplasty, JACC 27(3), 536-542 (1996).
Haverstick et al., Inhibition of Platelet Adhesion to Fibronectin, Fibrinogen, and von Willebrand Factor Substrates by a Synthetic Tetrapeptide Derived From the Cell-Binding Domain of Fibronectin, Blood 66(4), 946-952 (1985).
Barrett et al., Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-11b/111a receptor antagonist, in healthy men, Clinical Pharmacology & Therapeutics 56(4), 377-388 (1994).
Ginsberg et al., Inhibition of Fibronectin Binding to Platelets by Proteolytic Fragments and Synthetic Peptides Which Support Fibroblast Adhesion*, Journal of Biological Chemistry 260(7), 3931-3936 (1985).
Gartner et al., The Tetrapeptide Analogue of the Cell Attachment Site of Fibronectin Inhibits Platelet Aggregation and Fibrinogen Binding to Activated Platelets*, Journal of Biological Chemistry 260(22), 11891-11894 (1985).
Dettori et al., Human Pharmacology of a Low-Molecular-Weight Heparin (Alfa-LMWH): An Update, Medicinal Research Reviews 12(4), 373-389 (1992).
Zammit et al., Low-Affinity Material Does Not Contribute to the Antithrombotic Activity of Orgaran (Org 10172) in Human Plasma, Thromb. Haemostas. 71(6), 759-767 (1994).
Lynch et al., Nonpeptide Glycoprotein 11b/111a Inhibitors 5. Antithrombotic Effects of MK-0383, Jnl of Pharmacology & Experimental Therapeutics 272(1), 2-32 (1995).
Barrowcliffe et al., Anticoagulant Activities of Lung & Mucous Heparins, Thrombosis Research 12, 27-36 (1977).
Gent et al., Low-Molecular-Weight Heparinoid Orgaran In More Effective Than Aspirin in the Prevention of Venous Thromboembolism After Surgery for Hip Fracture, Circulation 93(1) 80-84 (1996).
Catalfamo et al., Isolation of Platelets from Laboratory Animals, Methods in Enzymology 169, 117-133 (1989).
Peerlinck et al., MK-383 (L-700,462), a Selective Nonpeptide Platelet Glycoprotein iib/iiia Antagonist, Is Active in Man, Circulation 88(4), Part 1, 1512-1517 (1993).
Fussi, F. et al., Methods of Heparin depolymerization: oligoheteropolysaccharides as antithrombotic agents. New frontiers in prophylaxis of venous thrombosis., pp. 339-345.
Frederick, Leo G. et al., The Protective Dose of the Potent GPIIb/IIIa Antagonist SC-54701A Is Reduced When Used in Combination With Aspirin and Heparin in a Canine Model of Coronary Artery Thrombosis.
Green et al., Interaction of Low Molecular Weight Heparin With Ketorolac, J. Lab Clin. Med, pp. 583-587 (1996).
Leadley, Robt. J. Jr et al., Inhibition of Repetitive Thrombus Formation in the Stenosed Canine Coronary Artery by Enoxaparin, But Not by Unfractionated Heparin, Arterioscler. Thromb. Vasc. Biol., vol. 18, pp. 908-914 (1998).
Bernat, A. et al., The Antithrombotic Efficacy of the GP IIb/IIIa Antagonist SR121787 is Potentiated by Antithrombin-Dependent Factor Xa Inhibition Without an Increase in the Bleeding Risk in the Rabbit, Journal of Cardio. Pharm. vol. 33, No. 4, pp. 573-579 (1999).
New International Study of ReoPro in Acute Coronary Syndrome Underway; Substudy Will Assess Safety of Reopro(R) and Fragmin(R) in Combination, PR Newswire (4); Mar. 30, 1999.
Verheggen, P.W.H.M. et al., Inflammatory Status as a Main Determinant of Outcome in Patients with Unstable Angina, Independent of Coagulation Activation and Endothelial Cell Function, European Heart Journal, vol. 20, pp. 567-574 (1999).
Curaudeau Alain H.
Dunwiddie Christopher T.
Leadley Robert J.
Perrone Mark H.
Uzan Andre
Aventis Pharmaceuticals Products Inc.
Fay Zohreh
Hansen Christine M.
Oehler Ross J.
Parker III Raymond S.
LandOfFree
Pharmaceutical composition comprising a compound having anti-Xa does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical composition comprising a compound having anti-Xa , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical composition comprising a compound having anti-Xa will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2006943